FLGT Fulgent Expected net earnings per share growth this year

Fulgent Genetics, Inc. (FLGT) is strengthening its position in oncology diagnostics through its proprietary sequencing IT system, despite pricing competition. The current YoY EPS growth reflects the asset's dynamics, where -506.50 determines the current status of the parameter. An efficient courier network is boosting service margins, while the digitalization of test results reduces energy consumption and paper waste, aligning with ESG environmental standards.

Fulgent Genetics - FLGT Net earnings per share growth this year (period 07/04/2022 - 11/15/2026)

Financial and market metric breakdowns for fulgentgenetics.com (FLGT)

- current quotes and average value forecast:

Market Chart Fulgent|FLGT - Price Target Chart

- market capitalization data:

Market Capitalization Fulgent Genetics|FLGT - Enterprise Value

- shareholders' equity book value data:

Share Book Value Fulgent Genetics|FLGT - Company Net Assets|Market Capitalization to Book Value Ratio fulgentgenetics.com|FLGT - Aggregate Company Assets

- debt burden and liquidity indicators:

- financial results and valuation multiples details:

FLGT - Net Income|Expected Net Income Fulgent Genetics, Inc.|FLGT - P/E Multiple|Forward Price to Earnings Multiple Fulgent Genetics, Inc.|FLGT - PEG Multiple|Company Value to EBITDA Fulgent Genetics, Inc.|FLGT - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Fulgent Genetics|FLGT - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months fulgentgenetics.com|FLGT - Net earnings per share growth this year|Projected earnings per share increase next year Fulgent Genetics, Inc.

- company sales and revenue statistics:

FLGT - Revenue and Sales Volume|Company Future Sales Fulgent Corp|FLGT - P/S Multiple|Forward Price-to-Revenue Multiple Fulgent Genetics, Inc.

Fundamental valuation:FLGT Fulgent

Finished products of Fulgent Genetics, Inc.

Optimizing courier routes for the express delivery of genetic tests increases margins for Fulgent Genetics, Inc. (FLGT), directly impacting net income. This indicator captures the growth rate of earnings per share compared to the same period last year, allowing investors to assess the sustainability of the business model through year-over-year EPS changes to identify the long-term fundamental trend.

Main competitors